The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 131)
Access to Data & Biospecimens, 2018
Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC
The diagnosis and treatment of Parkinson's disease (PD) would be aided by the availability of direct and highly sensitive tests for the abnormal clusters of the protein a-synuclein (αSyn) that appears to cause the disease. Two such tests have been reported by other laboratories, but these tests take 5-13 days to perform in the laboratory. We have developed a s...
Researchers: Byron Caughey,
Mitochondrial Biomarkers Program, 2018
Leucine-rich repeat kinase 2 (LRRK2) is the greatest known genetic contributor to Parkinson's disease (PD). Research studies have linked mutations (changes) in the LRRK2 gene to DNA damage in mitochondria, powerhouses of the cell. Mitochondrial DNA (mtDNA) damage can be used for examining molecular mechanisms and screening therapeutic strategies for PD. However, while existing ass...
Researchers: Gang Fang, PhD
Research Grant, 2018
The PINK1 and parkin proteins jointly ensure quality control of mitochondria, the cell's powerhouse. Together they modify damaged mitochondria with phosphorylated ubiquitin (pS65-Ub), which appears to label the mitochondria for degradation. In some genetic forms of Parkinson's, PINK1 and parkin activity is lost, and mitochondrial dysfunction is seen in the broader Parkinson's popul...
Researchers: Wolfdieter Springer, PhD
Research Grant, 2017
Evidence suggests that increased activity of the c-abl protein in the brain may contribute to the development and progression of Parkinson's disease (PD). Nilotinib, a drug that inhibits c-abl, has recently shown promise as a potential therapeutic. In its activated state, c-abl is modified with a phosphate group (protein regulator) and measuring the extent of phosphorylation may b...
Researchers: David R. Walt, PhD
Research Grant, 2017
Mutations in the LRRK2 and GBA genes increase the risk for Parkinson's disease (PD). The mechanism by which these mutations increase PD risk is unknown. One potential explanation may be that the activity of the enzymes (chemicals that increase chemical reactions) encoded by these genes is increased (as suspected in LRRK2) or reduced (as suspected in GBA). The purpose of this stud...